4 1627

Cited 0 times in

Cited 0 times in

Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0

Authors
 Di Wu  ;  Jia-Horng Kao  ;  Teerha Piratvisuth  ;  Xiaojing Wang  ;  Patrick T F Kennedy  ;  Motoyuki Otsuka  ;  Sang Hoon Ahn  ;  Yasuhito Tanaka  ;  Guiqiang Wang  ;  Zhenghong Yuan  ;  Wenhui Li  ;  Young-Suk Lim  ;  Junqi Niu  ;  Fengmin Lu  ;  Wenhong Zhang  ;  Zhiliang Gao  ;  Apichat Kaewdech  ;  Meifang Han  ;  Weiming Yan  ;  Hong Ren  ;  Peng Hu  ;  Sainan Shu  ;  Paul Yien Kwo  ;  Fu-Sheng Wang  ;  Man-Fung Yuen  ;  Qin Ning 
Citation
 CLINICAL AND MOLECULAR HEPATOLOGY, Vol.31(Suppl.) : S134-S164, 2025-02 
Journal Title
CLINICAL AND MOLECULAR HEPATOLOGY
ISSN
 2287-2728 
Issue Date
2025-02
MeSH
Antiviral Agents* / therapeutic use ; Biomarkers ; Consensus ; Hepatitis B Surface Antigens / blood ; Hepatitis B virus / genetics ; Hepatitis B, Chronic* / diagnosis ; Hepatitis B, Chronic* / drug therapy ; Humans ; Immunologic Factors / therapeutic use ; Treatment Outcome
Keywords
Antiviral Agents ; Chronic hepatitis B ; Consensus ; HBsAg ; Immunologic Factors
Abstract
As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.
Files in This Item:
T202505573.pdf Download
DOI
10.3350/cmh.2024.0780
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Ahn, Sang Hoon(안상훈) ORCID logo https://orcid.org/0000-0002-3629-4624
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/207249
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links